NASDAQ
ONCT

Oncternal Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Oncternal Therapeutics Inc Stock Price

Vitals

Today's Low:
$0.3202
Today's High:
$0.3452
Open Price:
$0.331
52W Low:
$0.26
52W High:
$1.33
Prev. Close:
$0.32
Volume:
141291

Company Statistics

Market Cap.:
$17.70 million
Book Value:
0.769
Revenue TTM:
$862000
Operating Margin TTM:
-5212.07%
Gross Profit TTM:
$-31490000
Profit Margin:
0%
Return on Assets TTM:
-42.45%
Return on Equity TTM:
-72.12%

Company Profile

Oncternal Therapeutics Inc had its IPO on 2004-02-03 under the ticker symbol ONCT.

The company operates in the Healthcare sector and Biotechnology industry. Oncternal Therapeutics Inc has a staff strength of 30 employees.

Stock update

Shares of Oncternal Therapeutics Inc opened at $0.33 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.32 - $0.35, and closed at $0.33.

This is a +1.88% increase from the previous day's closing price.

A total volume of 141,291 shares were traded at the close of the day’s session.

In the last one week, shares of Oncternal Therapeutics Inc have increased by +8.67%.

Oncternal Therapeutics Inc's Key Ratios

Oncternal Therapeutics Inc has a market cap of $17.70 million, indicating a price to book ratio of 0.8794 and a price to sales ratio of 27.6427.

In the last 12-months Oncternal Therapeutics Inc’s revenue was $862000 with a gross profit of $-31490000 and an EBITDA of $0. The EBITDA ratio measures Oncternal Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Oncternal Therapeutics Inc’s operating margin was -5212.07% while its return on assets stood at -42.45% with a return of equity of -72.12%.

In Q2, Oncternal Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 44.5%.

Oncternal Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.73 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Oncternal Therapeutics Inc’s profitability.

Oncternal Therapeutics Inc stock is trading at a EV to sales ratio of 0.8526 and a EV to EBITDA ratio of 0.2487. Its price to sales ratio in the trailing 12-months stood at 27.6427.

Oncternal Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$50.77 million
Total Liabilities
$4.83 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Oncternal Therapeutics Inc ended 2024 with $50.77 million in total assets and $0 in total liabilities. Its intangible assets were valued at $50.77 million while shareholder equity stood at $-178753000.00.

Oncternal Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $4.83 million in other current liabilities, 59000.00 in common stock, $-178753000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $15.83 million and cash and short-term investments were $45.50 million. The company’s total short-term debt was $145,000 while long-term debt stood at $0.

Oncternal Therapeutics Inc’s total current assets stands at $50.08 million while long-term investments were $0 and short-term investments were $29.67 million. Its net receivables were $0 compared to accounts payable of $2.22 million and inventory worth $0.

In 2024, Oncternal Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Oncternal Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.33
52-Week High
$1.33
52-Week Low
$0.26
Analyst Target Price
$1.9

Oncternal Therapeutics Inc stock is currently trading at $0.33 per share. It touched a 52-week high of $1.33 and a 52-week low of $1.33. Analysts tracking the stock have a 12-month average target price of $1.9.

Its 50-day moving average was $0.36 and 200-day moving average was $0.62 The short ratio stood at 1.36 indicating a short percent outstanding of 0%.

Around 862.3% of the company’s stock are held by insiders while 1957.4% are held by institutions.

Frequently Asked Questions About Oncternal Therapeutics Inc

The stock symbol (also called stock or share ticker) of Oncternal Therapeutics Inc is ONCT

The IPO of Oncternal Therapeutics Inc took place on 2004-02-03

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$10.68
-0.2
-1.84%
$13.52
0.04
+0.3%
$13.55
0.28
+2.11%
$932.3
-22.8
-2.39%
$3.97
0.03
+0.76%
$18.29
0.35
+1.95%
$46.18
-4.4
-8.7%
$2.43
-0.05
-2.02%
$0.16
0.01
+4.51%
$5.22
-0.11
-2.06%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company’s clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

Address

12230 El Camino Real, San Diego, CA, United States, 92130